ARGX:NSD-argenx NV ADR (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 551.71

Change

-1.17 (-0.21)%

Market Cap

USD 33.21B

Volume

0.27M

Analyst Target

USD 254.56
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. Address: Laarderhoogtweg 25, Amsterdam, Netherlands, 1101EB

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.72 (+1.00%)

USD 121.32B
REGN Regeneron Pharmaceuticals Inc

-4.54 (-0.49%)

USD 103.77B
ALNY Alnylam Pharmaceuticals Inc

-3.20 (-1.12%)

USD 36.83B
BGNE BeiGene Ltd

-10.54 (-4.87%)

USD 24.57B
MRNA Moderna Inc

-0.50 (-0.91%)

USD 20.52B
RPRX Royalty Pharma Plc

+0.04 (+0.15%)

USD 16.47B
UTHR United Therapeutics Corporatio..

+8.60 (+2.44%)

USD 15.69B
SMMT Summit Therapeutics PLC

-3.18 (-14.57%)

USD 15.13B
PCVX Vaxcyte Inc

+0.55 (+0.52%)

USD 13.95B
BMRN Biomarin Pharmaceutical Inc

-3.23 (-4.62%)

USD 13.32B

ETFs Containing ARGX

BBH VanEck Biotech ETF 4.60 % 0.35 %

-0.05 (0.00%)

USD 0.45B
FBT:LSE First Trust Global Funds .. 3.51 % 0.00 %

+19.60 (+0.00%)

USD 8.17M
FBTU:LSE First Trust Global Funds .. 3.51 % 0.00 %

+0.27 (+0.00%)

USD 8.17M
BMED BlackRock Future Health E.. 3.36 % 0.00 %

-0.02 (0.00%)

USD 4.17M
2B78:XETRA iShares Healthcare Innova.. 2.15 % 0.00 %

+0.01 (+0.00%)

USD 1.14B
2B78:F iShares Healthcare Innova.. 2.15 % 0.00 %

N/A

N/A
HEAL:SW iShares Healthcare Innova.. 2.04 % 0.00 %

+0.01 (+0.00%)

N/A
XSDR:LSE Xtrackers MSCI Europe Hea.. 1.92 % 0.00 %

-181.00 (0.00%)

USD 0.25B
DXSE:XETRA Xtrackers - Stoxx Europe .. 1.92 % 0.00 %

-2.45 (0.00%)

USD 0.14B
ESIH:LSE iShares MSCI Europe Healt.. 1.86 % 0.00 %

-0.06 (0.00%)

USD 0.66B
2B70:F iShares NASDAQ US Biotech.. 1.81 % 0.00 %

N/A

USD 0.52B
IBBQ Invesco Nasdaq Biotechnol.. 1.80 % 0.00 %

-0.11 (0.00%)

USD 0.04B
2B70:XETRA iShares Nasdaq US Biotech.. 1.78 % 0.00 %

-0.02 (0.00%)

USD 0.52B
TEET:LSE VanEck Sustainable Europe.. 1.45 % 0.00 %

-0.65 (0.00%)

USD 0.05B
V3ET:F VanEck Vectors ETFs N.V. .. 1.36 % 0.00 %

-0.92 (0.00%)

USD 0.05B
V3ET:XETRA VanEck Sustainable Europe.. 1.36 % 0.00 %

-0.92 (0.00%)

USD 0.05B
TEET:SW VanEck Sustainable Europe.. 1.36 % 0.00 %

N/A

USD 0.05B
TEGB:LSE VanEck Sustainable Europe.. 1.25 % 0.00 %

-0.47 (0.00%)

N/A
BIB ProShares Ultra Nasdaq Bi.. 1.18 % 0.95 %

-0.61 (0.00%)

USD 0.09B
2B77:XETRA iShares Ageing Population.. 0.71 % 0.00 %

-0.04 (0.00%)

USD 0.50B
2B77:F iShares Ageing Population.. 0.71 % 0.00 %

-0.07 (0.00%)

N/A
AGED:SW iShares Ageing Population.. 0.61 % 0.00 %

N/A

N/A
TSGB:LSE VanEck Sustainable World .. 0.59 % 0.00 %

-0.02 (0.00%)

USD 0.76B
TSWE:F VanEck Sustainable World .. 0.56 % 0.00 %

-0.15 (0.00%)

USD 0.72B
TSWE:XETRA VanEck Sustainable World .. 0.56 % 0.00 %

-0.28 (0.00%)

USD 0.72B
TSWE:SW VanEck Sustainable World .. 0.56 % 0.00 %

N/A

USD 0.77B
TSWE:LSE VanEck Sustainable World .. 0.49 % 0.00 %

-0.06 (0.00%)

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+1.40 (+0.00%)

N/A
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

+0.04 (+0.00%)

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

-0.75 (0.00%)

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+3.00 (+0.00%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+0.08 (+0.00%)

N/A
HLTH:LSE SPDR® MSCI Europe Health.. 0.00 % 0.00 %

-3.33 (0.00%)

N/A
STW:PA SPDR® MSCI Europe Health.. 0.00 % 0.00 %

-3.15 (0.00%)

USD 0.75B
DXSE:F Xtrackers Stoxx Europe 60.. 0.00 % 0.00 %

N/A

N/A
EXV4:F iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

N/A
SPYH:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

-3.25 (0.00%)

N/A
EXV4:XETRA iShares STOXX Europe 600 .. 0.00 % 0.00 %

-1.58 (0.00%)

USD 0.70B
SPYH:XETRA SPDR® MSCI Europe Health.. 0.00 % 0.00 %

-3.15 (0.00%)

USD 0.66B
ESIH:F Ishares VI PLC - Ishares .. 0.00 % 0.00 %

-0.11 (0.00%)

USD 0.66B
ESIH:XETRA iShares MSCI Europe Healt.. 0.00 % 0.00 %

-0.10 (0.00%)

USD 0.60B
HEAE:LSE SPDR® MSCI Europe Health.. 0.00 % 0.00 %

-1.91 (0.00%)

N/A
STWX:SW SPDR® MSCI Europe Health.. 0.00 % 0.00 %

-3.05 (0.00%)

USD 0.74B
SXDPEX:SW iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

USD 0.44B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 45.29% 54% F 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.29% 54% F 75% C
Trailing 12 Months  
Capital Gain 11.51% 37% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.51% 37% F 49% F
Trailing 5 Years  
Capital Gain 338.81% 74% C 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 338.81% 74% C 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 28.45% 71% C- 81% B-
Dividend Return 28.45% 71% C- 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.73% 78% C+ 54% F
Risk Adjusted Return 81.91% 99% N/A 92% A
Market Capitalization 33.21B 99% N/A 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector